Clinical Trials Browser

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT00984425 2014-12-02

The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors

Phase 1 Completed

30 enrolled

Other solid neoplasm

Solid Tumors

NCT01245205 2014-10-23

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Phase 1 Completed

28 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00313599 2014-07-02

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

28 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Dysgerminoma, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Central Nervous System Neoplasms

NCT00544804 2014-07-02

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

Phase 1 Completed

41 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00623064 2014-07-01

Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer

Phase 1 Completed

18 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT00470847 2014-05-22

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

Phase 1 Completed

35 enrolled 10 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00513058 2014-01-14

Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer

Phase 1 Completed

33 enrolled

Breast

Breast Neoplasms

NCT00316875 2013-11-08

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

Phase 1 Completed

23 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01184482 2013-10-31

TYKERB-ITUX 1

Phase 1 Completed

22 enrolled

GastrointestinalHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Colorectal Neoplasms

NCT00495872 2012-10-18

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Phase 1 Completed

204 enrolled

Other solid neoplasm

Solid Tumors

NCT00614978 2012-09-19

LAPTEM

Phase 1 Completed

18 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00389922 2012-04-19

Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

22 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT01133912 2012-01-04

PGT

Phase 1 Completed

13 enrolled

Breast

Breast Neoplasms

Clinical Trials

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

LAPATAM

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

Bevacizumab in Multiple Phase I Combinations

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

STELA

GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

GW572016 In Patients With Advanced Or Metastatic Breast Cancer

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

Rollover Study Of Lapatinib In Cancer Patients

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib

Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Lapatinib With Sirolimus or Metformin

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

TYKERB-ITUX 1

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

LAPTEM

Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors

PGT